Clinical Trial Results:
A Phase IIb, randomized, observer-blind, placebo controlled, multicenter primary/booster therapeutic vaccination study to determine efficacy and safety of F4co/ AS01B vaccine, administered intramuscularly according to either a two dose (0, 4 weeks) or a three dose (0, 4, 28 weeks) schedule in ART-naïve HIV-1 infected persons aged 18-55 years
Summary
|
|
EudraCT number |
2010-021356-26 |
Trial protocol |
DE ES |
Global completion date |
05 Nov 2012
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
27 Apr 2016
|
First version publication date |
09 Jul 2014
|
Other versions |
|
Summary report(s) |
111679 Clinical study result summary |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.